Logo image of MNPR

MONOPAR THERAPEUTICS INC (MNPR) Stock Fundamental Analysis

USA - NASDAQ:MNPR - US61023L2079 - Common Stock

80.6 USD
+4.17 (+5.46%)
Last: 11/18/2025, 8:00:01 PM
80.6 USD
0 (0%)
After Hours: 11/18/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MNPR. MNPR was compared to 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MNPR as it has an excellent financial health rating, but there are worries on the profitability. MNPR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MNPR had negative earnings in the past year.
MNPR had a negative operating cash flow in the past year.
In the past 5 years MNPR always reported negative net income.
MNPR had a negative operating cash flow in each of the past 5 years.
MNPR Yearly Net Income VS EBIT VS OCF VS FCFMNPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

MNPR has a better Return On Assets (-32.12%) than 64.92% of its industry peers.
MNPR has a better Return On Equity (-33.15%) than 75.23% of its industry peers.
Industry RankSector Rank
ROA -32.12%
ROE -33.15%
ROIC N/A
ROA(3y)-73.47%
ROA(5y)-60.42%
ROE(3y)-94.55%
ROE(5y)-74.37%
ROIC(3y)N/A
ROIC(5y)N/A
MNPR Yearly ROA, ROE, ROICMNPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MNPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNPR Yearly Profit, Operating, Gross MarginsMNPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

9

2. Health

2.1 Basic Checks

The number of shares outstanding for MNPR has been increased compared to 1 year ago.
MNPR has less shares outstanding than it did 5 years ago.
MNPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MNPR Yearly Shares OutstandingMNPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MNPR Yearly Total Debt VS Total AssetsMNPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

MNPR has an Altman-Z score of 180.05. This indicates that MNPR is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 180.05, MNPR belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
MNPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 180.05
ROIC/WACCN/A
WACCN/A
MNPR Yearly LT Debt VS Equity VS FCFMNPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 33.94 indicates that MNPR has no problem at all paying its short term obligations.
MNPR's Current ratio of 33.94 is amongst the best of the industry. MNPR outperforms 98.12% of its industry peers.
A Quick Ratio of 33.94 indicates that MNPR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 33.94, MNPR belongs to the top of the industry, outperforming 98.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 33.94
Quick Ratio 33.94
MNPR Yearly Current Assets VS Current LiabilitesMNPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MNPR have decreased strongly by -67.39% in the last year.
EPS 1Y (TTM)-67.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.26% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.13%
EPS Next 2Y4.93%
EPS Next 3Y6.48%
EPS Next 5Y19.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNPR Yearly Revenue VS EstimatesMNPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
MNPR Yearly EPS VS EstimatesMNPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MNPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNPR Price Earnings VS Forward Price EarningsMNPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNPR Per share dataMNPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.93%
EPS Next 3Y6.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MNPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MONOPAR THERAPEUTICS INC

NASDAQ:MNPR (11/18/2025, 8:00:01 PM)

After market: 80.6 0 (0%)

80.6

+4.17 (+5.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06
Earnings (Next)03-30 2026-03-30/amc
Inst Owners51.83%
Inst Owner Change32.4%
Ins Owners4.72%
Ins Owner Change-108.28%
Market Cap532.77M
Revenue(TTM)N/A
Net Income(TTM)-17.30M
Analysts84.44
Price Target113.82 (41.22%)
Short Float %5.12%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.26%
Min EPS beat(2)27.3%
Max EPS beat(2)45.21%
EPS beat(4)3
Avg EPS beat(4)-111.38%
Min EPS beat(4)-541.92%
Max EPS beat(4)45.21%
EPS beat(8)6
Avg EPS beat(8)-48.61%
EPS beat(12)9
Avg EPS beat(12)-29.47%
EPS beat(16)11
Avg EPS beat(16)-21.4%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)14.64%
PT rev (3m)74.9%
EPS NQ rev (1m)7.13%
EPS NQ rev (3m)14%
EPS NY rev (1m)3.05%
EPS NY rev (3m)19.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.21
P/tB 10.21
EV/EBITDA N/A
EPS(TTM)-3.85
EYN/A
EPS(NY)-3.7
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS7.9
TBVpS7.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.12%
ROE -33.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.47%
ROA(5y)-60.42%
ROE(3y)-94.55%
ROE(5y)-74.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 33.94
Quick Ratio 33.94
Altman-Z 180.05
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y58.13%
EPS Next 2Y4.93%
EPS Next 3Y6.48%
EPS Next 5Y19.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-154.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.51%
OCF growth 3YN/A
OCF growth 5YN/A

MONOPAR THERAPEUTICS INC / MNPR FAQ

What is the ChartMill fundamental rating of MONOPAR THERAPEUTICS INC (MNPR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MNPR.


What is the valuation status for MNPR stock?

ChartMill assigns a valuation rating of 0 / 10 to MONOPAR THERAPEUTICS INC (MNPR). This can be considered as Overvalued.


What is the profitability of MNPR stock?

MONOPAR THERAPEUTICS INC (MNPR) has a profitability rating of 1 / 10.


What is the financial health of MONOPAR THERAPEUTICS INC (MNPR) stock?

The financial health rating of MONOPAR THERAPEUTICS INC (MNPR) is 9 / 10.